Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice

References

• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073 - 81; http://dx.doi.org/10.1093/carcin/bgp127; PMID: 19468060
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357:539 - 45; http://dx.doi.org/10.1016/S0140-6736(00)04046-0; PMID: 11229684
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137 - 48; http://dx.doi.org/10.1016/j.immuni.2004.07.017; PMID: 15308095
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235 - 71; http://dx.doi.org/10.1146/annurev-immunol-031210-101324; PMID: 21219185
   PubMed Web of Science ®Google Scholar
• Fujita T, Taira S, Kodama N, Matsushita M, Fujita T. Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway. Jpn J Cancer Res 1995; 86:187 - 92; http://dx.doi.org/10.1111/j.1349-7006.1995.tb03038.x; PMID: 7730143
   PubMedGoogle Scholar
• Swierzko AS, Kilpatrick DC, Cedzynski M. Mannan-binding lectin in malignancy. Mol Immunol 2013; 55:16 - 21; http://dx.doi.org/10.1016/j.molimm.2012.09.005; PMID: 23062612
   PubMed Web of Science ®Google Scholar
• Gao LJ, Gu PQ, Fan WM, Liu Z, Qiu F, Peng YZ, Guo XR. The role of gC1qR in regulating survival of human papillomavirus 16 oncogene-transfected cervical cancer cells. Int J Oncol 2011; 39:1265 - 72; PMID: 21725590
   PubMed Web of Science ®Google Scholar
• Vollmers HP, Brändlein S. Natural antibodies and cancer. N Biotechnol 2009; 25:294 - 8; http://dx.doi.org/10.1016/j.nbt.2009.03.016; PMID: 19442595
   PubMed Web of Science ®Google Scholar
• Hamaï A, Duperrier-Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, Canzonieri V, Perin T, Classe JM, Campone M, et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS One 2011; 6:e21129; http://dx.doi.org/10.1371/journal.pone.0021129; PMID: 21747904
   PubMed Web of Science ®Google Scholar
• Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice R, Hanash SM, Disis ML. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 2012; 5:1036 - 43; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0558; PMID: 22715141
   PubMed Web of Science ®Google Scholar
• Stover C. Dual role of complement in tumour growth and metastasis (Review). [Review] Int J Mol Med 2010; 25:307 - 13; http://dx.doi.org/10.3892/ijmm_00000346; PMID: 20127033
   PubMed Web of Science ®Google Scholar
• Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785 - 97; http://dx.doi.org/10.1038/ni.1923; PMID: 20720586
   PubMed Web of Science ®Google Scholar
• Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, Lambris JD, Coukos G, Scholler N. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012; 14:994 - 1004; PMID: 23226093
   PubMed Web of Science ®Google Scholar
• Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005; 5:184 - 98; http://dx.doi.org/10.1038/nrc1565; PMID: 15738982
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6:204 - 16; http://dx.doi.org/10.1038/nrc1815; PMID: 16498443
   PubMed Web of Science ®Google Scholar
• Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90:175 - 213; http://dx.doi.org/10.1016/S0065-2776(06)90005-4; PMID: 16730264
   PubMed Web of Science ®Google Scholar
• Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 2008; Chapter 20:Unit 20 9 1- 9-10.
   Google Scholar
• Conti L, Lanzardo S, Iezzi M, Montone M, Bolli E, Brioschi C, Maiocchi A, Forni G, Cavallo F. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αv β3 integrins. Contrast Media Mol Imaging 2013; 8:350 - 60; http://dx.doi.org/10.1002/cmmi.1529; PMID: 23613438
   PubMed Web of Science ®Google Scholar
• Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13:58 - 68; http://dx.doi.org/10.1016/j.ccr.2007.12.003; PMID: 18167340
   PubMed Web of Science ®Google Scholar
• Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, Trinchieri G, Colombo MP, Chiodoni C. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 2010; 70:7764 - 75; http://dx.doi.org/10.1158/0008-5472.CAN-10-0471; PMID: 20924115
   PubMed Web of Science ®Google Scholar
• Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010; 14:2803 - 15; http://dx.doi.org/10.1111/j.1582-4934.2009.00926.x; PMID: 19818098
   PubMed Web of Science ®Google Scholar
• Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P, Smyth MJ. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 2007; 67:5454 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-06-4084; PMID: 17545627
   PubMed Web of Science ®Google Scholar
• Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolò C, Ambrosino E, Merighi IF, Musiani P, et al. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 2010; 184:6124 - 32; http://dx.doi.org/10.4049/jimmunol.0901215; PMID: 20435927
   PubMed Web of Science ®Google Scholar
• Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66:7734 - 40; http://dx.doi.org/10.1158/0008-5472.CAN-06-1432; PMID: 16885376
   PubMed Web of Science ®Google Scholar
• Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005; 11:1941 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-04-1873; PMID: 15756020
   PubMed Web of Science ®Google Scholar
• Calogero RA, Cordero F, Forni G, Cavallo F. Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res 2007; 9:211; http://dx.doi.org/10.1186/bcr1745; PMID: 17705881
   PubMed Web of Science ®Google Scholar
• Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells. Nat Immunol 2013; 14:162 - 71; http://dx.doi.org/10.1038/ni.2499; PMID: 23263555
   PubMed Web of Science ®Google Scholar
• Kwan WH, van der Touw W, Paz-Artal E, Li MO, Heeger PS. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med 2013; 210:257 - 68; http://dx.doi.org/10.1084/jem.20121525; PMID: 23382542
   PubMed Web of Science ®Google Scholar
• Langer HF, Chung KJ, Orlova VV, Choi EY, Kaul S, Kruhlak MJ, Alatsatianos M, DeAngelis RA, Roche PA, Magotti P, et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116:4395 - 403; http://dx.doi.org/10.1182/blood-2010-01-261503; PMID: 20625009
   PubMed Web of Science ®Google Scholar
• Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102:2138 - 45; http://dx.doi.org/10.1182/blood-2003-01-0190; PMID: 12750171
   PubMed Web of Science ®Google Scholar
• Brunn GJ, Saadi S, Platt JL. Constitutive repression of interleukin-1alpha in endothelial cells. Circ Res 2008; 102:823 - 30; http://dx.doi.org/10.1161/CIRCRESAHA.107.165332; PMID: 18292602
   PubMed Web of Science ®Google Scholar
• Muto S, Sakuma K, Taniguchi A, Matsumoto K. Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens. Biol Pharm Bull 1999; 22:347 - 52; http://dx.doi.org/10.1248/bpb.22.347; PMID: 10328552
   PubMed Web of Science ®Google Scholar
• Halperin JA, Taratuska A, Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993; 91:1974 - 8; http://dx.doi.org/10.1172/JCI116418; PMID: 8486768
   PubMed Web of Science ®Google Scholar
• Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 1992; 22:1207 - 13; http://dx.doi.org/10.1002/eji.1830220515; PMID: 1577063
   PubMed Web of Science ®Google Scholar
• Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9:1225 - 35; http://dx.doi.org/10.1038/ni.1655; PMID: 18820683
   PubMed Web of Science ®Google Scholar
• Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y, Hu X, Aggarwal D, Zhang HG, Yan J. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012; 189:2985 - 94; http://dx.doi.org/10.4049/jimmunol.1200846; PMID: 22914051
   PubMed Web of Science ®Google Scholar
• Schwartz-Albiez R, Laban S, Eichmüller S, Kirschfink M. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?. Autoimmun Rev 2008; 7:491 - 5; http://dx.doi.org/10.1016/j.autrev.2008.03.012; PMID: 18558368
   PubMed Web of Science ®Google Scholar
• Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004; 113:709 - 17; PMID: 14991069
   PubMed Web of Science ®Google Scholar
• Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 2010; 184:4170 - 7; http://dx.doi.org/10.4049/jimmunol.0903375; PMID: 20220087
   PubMed Web of Science ®Google Scholar
• Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother 2006; 55:987 - 95; http://dx.doi.org/10.1007/s00262-006-0136-8; PMID: 16485129
   PubMed Web of Science ®Google Scholar
• Vĕtvicka V, Hanikýrová M, Vĕtvicková J, Ross GD. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Clin Exp Immunol 1999; 115:229 - 35; http://dx.doi.org/10.1046/j.1365-2249.1999.00800.x; PMID: 9933447
   PubMed Web of Science ®Google Scholar
• Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, Watanabe M, Maruyama T, Kawaguchi Y, Inoue S, et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 2012; 1:1104 - 10; http://dx.doi.org/10.4161/onci.21056; PMID: 23170258
   PubMed Web of Science ®Google Scholar
• Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 2012; 188:2136 - 45; http://dx.doi.org/10.4049/jimmunol.1102237; PMID: 22301547
   PubMed Web of Science ®Google Scholar
• Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008; 28:425 - 35; http://dx.doi.org/10.1016/j.immuni.2008.02.001; PMID: 18328742
   PubMed Web of Science ®Google Scholar
• Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185:5628 - 36; http://dx.doi.org/10.4049/jimmunol.0903678; PMID: 20870944
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682 - 7; http://dx.doi.org/10.1038/nm1419; PMID: 16715088
   PubMed Web of Science ®Google Scholar
• O’Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012; 209:1869 - 82; http://dx.doi.org/10.1084/jem.20112738; PMID: 22927549
   PubMed Web of Science ®Google Scholar
• Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012; 189:4674 - 83; http://dx.doi.org/10.4049/jimmunol.1201654; PMID: 23028051
   PubMed Web of Science ®Google Scholar
• Trendelenburg M, Fossati-Jimack L, Cortes-Hernandez J, Turnberg D, Lewis M, Izui S, Cook HT, Botto M. The role of complement in cryoglobulin-induced immune complex glomerulonephritis. J Immunol 2005; 175:6909 - 14; PMID: 16272350
   PubMed Web of Science ®Google Scholar
• Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133 - 42; PMID: 11046045
   PubMed Web of Science ®Google Scholar
• Arigoni M, Barutello G, Lanzardo S, Longo D, Aime S, Curcio C, Iezzi M, Zheng Y, Barkefors I, Holmgren L, et al. A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis 2012; 15:305 - 16; http://dx.doi.org/10.1007/s10456-012-9263-3; PMID: 22426512
   PubMed Web of Science ®Google Scholar